Searched for: school:LISOM
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
Dani, Sourbha S; Makwana, Bhargav; Khadke, Sumanth; Kumar, Ashish; Jhund, Pardeep; Nasir, Khurram; Sattar, Naveed; Al-Kindi, Sadeer; Fonarow, Gregg; Butler, Javed; Bhatt, Deepak L; Kosiborod, Mikhail N; Nohria, Anju; Ganatra, Sarju
BACKGROUND:While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) is studied in randomized controlled trials, real-world outcomes may provide critical insights. OBJECTIVES/OBJECTIVE:The purpose of this study was to examine the cardiovascular benefits of tirzepatide vs GLP-1RA in people living with overweight or obesity, with T2DM, age ≥40 years, and pre-existing ischemic heart disease (IHD). METHODS:receiving either tirzepatide or GLP-1RA were identified and divided into 2 groups (tirzepatide vs GLP-1RA). After propensity score matching, Cox-proportional HRs were used to compare efficacy and safety outcomes during 1-year follow-up. RESULTS:Among 47,719 adults, 753 received tirzepatide, and 46,966 were on GLP-1RA. After propensity score matching, each group had 751 adults (mean age 59.9 ± 8.9 years, 46.5% females, 74.8% White adults in the tirzepatide group). Treatment with tirzepatide was associated with lower primary composite outcomes of acute myocardial infarction, ischemic stroke, and all-cause mortality (HR: 0.60, 95% CI: 0.43-0.84, P < 0.001). Individually, acute myocardial infarction (HR: 0.59, 95% CI: 0.38-0.91) and all-cause mortality (HR: 0.35, 95% CI: 0.14-0.88, P = 0.001) were also found to be favorable in the tirzepatide group. CONCLUSIONS:, and pre-existing IHD.
PMCID:12235410
PMID: 40447342
ISSN: 2772-963x
CID: 5990542
A re-look at the relevance of TSH and thyroid autoimmunity for pregnancy outcomes: Analyses of RCT data from PPCOS II and AMIGOS
Kuokkanen, Satu; Seungdamrong, Aimee; Santoro, Nanette; Lieman, Harry; Sun, Fangbai; Wild, Robert; Zhang, Heping; Pal, Lubna
OBJECTIVE:We examined if thyroid autoimmunity is relevant to the relationship between maternal TSH levels and pregnancy outcomes. DESIGN/METHODS:Retrospective cohort analysis of data from two randomized controlled trials (RCTs). SUBJECTS/METHODS:Participants of the Pregnancy in Polycystic Ovary Syndrome (PPCOS II, n = 746) and the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS, n = 832 with unexplained infertility) RCTs. EXPOSURE/METHODS:Pre-trial intervention levels of thyroid stimulating hormone (TSH) at threshold of ≥2.0 mU/L and thyroid peroxidase antibody (TPO-Ab) at titer threshold of ≥30 U/mL. MAIN OUTCOME/RESULTS:Live birth (primary outcome), pregnancy loss and preterm birth (secondary outcomes). Generalized linear model (GLM) analyses examined the relationship between exposure to TSH and TPO-Ab at specified thresholds with the specified outcomes; covariates adjusted for included age, body mass index, race, ethnicity, education, smoking, duration of infertility, PCOS (versus unexplained infertility) and randomized intervention arm in the respective RCTs. RESULTS:On adjusted analyses, live birth was significantly reduced in the exposed population (those with TSH ≥2.0 mU/L and TPO-Ab ≥30 U/mL, n= 117/1578, 7.4%, adjusted risk ratio [ARR] 0.55, 95% CI 0.35- 0.87) compared to the unexposed (those with TSH <2.0 mU/L and TPO-Ab <30 U/mL, n=865/1578, 54.8%). Furthermore, the risk of pregnancy loss and of early preterm birth (<32 weeks) was significantly higher in the exposed compared to the unexposed (ARR for pregnancy loss was 1.66, 95% CI 1.14- 2.42, and ARR for early preterm birth was 4. 82 (95% CI 1.53- 15.19). CONCLUSIONS:In women with TPO-Ab titers ≥30 U/mL, pregnancy outcomes may be compromised at TSH threshold of ≥2 mU/L. These findings of an interaction between TSH and TPO for pregnancy outcomes merit further investigation in prospective studies.
PMID: 39672366
ISSN: 1556-5653
CID: 5761982
Integrating patient advocacy groups in the development of clinical practice guidelines: comment on the article by Johnson et al [Letter]
Gupta, Nishant; Carsons, Steven E; Carteron, Nancy L; Scofield, Robert Hal; Lee, Augustine S; Thomas, Donald E; Moua, Teng; Ussavarungsi, Kamonpun; St Clair, E William; Meehan, Richard; Dunleavy, Kieron; Makara, Matt; Hammitt, Katherine Morland
PMID: 39605233
ISSN: 2151-4658
CID: 5767002
ACR Appropriateness Criteria® Colorectal Cancer Screening: 2024 Update
,; Thomas, Desencia E; Horvat, Natally; Fowler, Kathryn J; Birkholz, James H; Cash, Brooks D; Dane, Bari; Dbouk, Reema H; Hanna, Nader; Hurley, Janet; Korngold, Elena K; Pietryga, Jason A; Yeghiayan, Paula; Zell, Jason A; Zreloff, Jennifer; Kim, David H
This document serves to update the 2018 ACR Appropriateness Criteria® colorectal screening guidance document. In light of new recommendations from the US Preventative Services Task Force (USPSTF), an updated literature review of the imaging procedures for the screening of colorectal cancer was performed. Average-risk, elevated-risk, and high-risk individuals as well as those individuals who had an incomplete colonoscopy or were unable to tolerate colonoscopy were included. CT colonography without contrast was found to be usually appropriate for individuals at average and elevated risk between 45 to 75 years of age at initial screening. Additionally, CT colonography without contrast was found to be usually appropriate in individuals at average risk, elevated risk, and at high risk after incomplete colonoscopy or unable to tolerate colonoscopy. Other imaging procedures such as barium fluoroscopy and CT of the abdomen and pelvis were usually not appropriate. CT colonography without contrast, barium fluoroscopy, and CT of the abdomen and pelvis were usually not appropriate in high-risk individuals who can undergo a complete colonoscopy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
PMID: 40409877
ISSN: 1558-349x
CID: 5853692
Improving the Transition From Medical School to Residency in Obstetrics and Gynecology: Lessons Learned and Future Directions
Hammoud, Maya M; Marzano, David A; Morgan, Helen K; Connolly, AnnaMarie; Banks, Erika; Strand, Eric; George, Karen; Ollendorff, Arthur T; Dalrymple, John L; Winkel, Abigail Ford
PMCID:12080506
PMID: 40386484
ISSN: 1949-8357
CID: 5852772
Utilization of Machine Learning Models to More Accurately Predict Case Duration in Primary Total Joint Arthroplasty
Dellicarpini, Gennaro; Passano, Brandon; Yang, Jie; Yassin, Sallie M; Becker, Jacob; Aphinyanaphongs, Yindalon; Capozzi, James
INTRODUCTION/BACKGROUND:Accurate operative scheduling is essential for the appropriation of operating room (OR) resources. We sought to implement a machine learning (ML) model to predict primary total hip (THA) and total knee arthroplasty (TKA) case time. METHODS:A total of 10,590 THAs and 12,179 TKAs between July 2017 and December 2022 were retrospectively identified. Cases were chronologically divided into training, validation, and test sets. The test set cohort included 1,588 TKAs and 1,204 THAs. There were four machine learning algorithms developed: linear ridge regression (LR), random forest (RF), XGBoost (XGB), and explainable boosting machine (EBM). Each model's case time estimate was compared to the scheduled estimate measured in 15-minute "wait" time blocks ("underbooking") and "excess" time blocks ("overbooking"). Surgical case time was recorded, and SHAP (Shapley Additive exPlanations) values were assigned to patient characteristics, surgical information, and the patient's medical condition to understand feature importance. RESULTS:The most predictive model input was "median previous 30 procedure case times." The XGBoost model outperformed the other models in predicting both TKA and THA case times. The model reduced TKA 'excess time blocks' by 85 blocks (P < 0.001) and 'wait time blocks' by 96 blocks (P < 0.001). The model did not significantly reduce 'excess time blocks' in THA (P = 0.89) but did significantly reduce 'wait time blocks' by 134 blocks (P < 0.001). In total, the model improved TKA operative booking by 181 blocks (2,715 minutes) and THA operative booking by 138 blocks (2,070 minutes). CONCLUSIONS:Machine learning outperformed a traditional method of scheduling total joint arthroplasty (TJA) cases. The median time of the prior 30 surgical cases was the most influential on scheduling case time accuracy. As ML models improve, surgeons should consider machine learning utilization in case scheduling; however, prior 30 surgical cases may serve as an adequate alternative.
PMID: 39477036
ISSN: 1532-8406
CID: 5747082
Blood pressure control in pregnant patients with chronic hypertension and diabetes: should <130/80 be the target?
Harper, Lorie M; Kuo, Hui-Chien; Boggess, Kim; Dugoff, Lorraine; Sibai, Baha; Lawrence, Kirsten; Hughes, Brenna L; Bell, Joseph; Aagaard, Kjersti; Edwards, Rodney K; Gibson, Kelly S; Haas, David M; Plante, Lauren; Metz, Torri D; Casey, Brian M; Esplin, Sean; Longo, Sherri; Hoffman, Matthew; Saade, George R; Hoppe, Kara; Foroutan, Janelle; Tuuli, Methodius G; Owens, Michelle Y; Simhan, Hyagriv N; Frey, Heather A; Rosen, Todd; Palatnik, Anna; August, Phyllis; Reddy, Uma M; Kinzler, Wendy; Su, Emily J; Krishna, Iris; Nguyen, Nguyet A; Norton, Mary E; Skupski, Daniel; El-Sayed, Yasser Y; Galis, Zorina S; Ambalavanan, Namasivayam; Oparil, Suzanne; Szychowski, Jeff M; Tita, Alan T N
BACKGROUND:The Chronic Hypertension and Pregnancy Study demonstrated that a target blood pressure of <140/90 mm Hg during pregnancy is associated with improved perinatal outcomes. Outside of pregnancy, pharmacologic therapy for patients with diabetes and hypertension is adjusted to a target blood pressure of <130/80 mm Hg. During pregnancy, patients with both diabetes and chronic hypertension may also benefit from tighter control with a target blood pressure <130/80 mm Hg. OBJECTIVE:We compared perinatal outcomes in patients with hypertension and diabetes who achieved blood pressure <130/80 vs 130 to 139/80 to 89 mm Hg. STUDY DESIGN/METHODS:This was a secondary analysis of a multcenter randomized controlled trial. Participants were included in this secondary analysis if they had diabetes diagnosed prior to pregnancy or at <20 weeks of gestation and at least 2 recorded blood pressure measurements prior to delivery. Average systolic and diastolic blood pressure were calculated using ambulatory antenatal blood pressures. The primary composite outcome was preeclampsia with severe features, indicated preterm birth <35 weeks, or placental abruption. Secondary outcomes were components of the primary outcome, cesarean delivery, fetal or neonatal death, neonatal intensive care unit admission, and small for gestational age. Comparisons were made between those with an average systolic blood pressure <130 mm Hg and average diastolic blood pressure <80 mm Hg and those with an average systolic blood pressure 130 to 139 mm Hg or diastolic blood pressure 80 to 89 mm Hg using Student's t test and chi-squared tests. Multivariable log-binomial regression models were used to evaluate risk ratios between blood pressure groups for dichotomous outcomes while accounting for baseline covariates. RESULTS:Of 434 participants included, 150 (34.6%) had an average blood pressure less than 130/80 mm Hg. Participants with an average blood pressure less than 130/80 were more likely to be on antihypertensive medications at the start of pregnancy and more likely to have newly diagnosed diabetes mellitus prior to 20 weeks. Participants with an average blood pressure less than 130/80 mm Hg were less likely to have the primary adverse perinatal outcome (19.3% vs 46.5%, adjusted relative risk 0.43, 95% confidence interval 0.30-0.61, P<.01), with decreased risks specifically of preeclampsia with severe features (adjusted relative risk 0.35, 95% confidence interval 0.23-0.54) and indicated preterm birth prior to 35 weeks (adjusted relative risk 0.44, 95% confidence interval 0.24-0.79). The risk of neonatal intensive care unit admission was lower in the lower blood pressure group (adjusted relative risk 0.74, 95% confidence interval 0.59-0.94). No differences were noted in cesarean delivery (adjusted relative risk 1.04, 95% confidence interval 0.90-1.20), fetal or neonatal death (adjusted relative risk 0.59, 95% confidence interval 0.12-2.92). Small for gestational age less than the 10th percentile was lower in the lower blood pressure group (adjusted relative risk 0.37, 95% confidence interval 0.14-0.96). CONCLUSION/CONCLUSIONS:In those with chronic hypertension and diabetes prior to 20 weeks, achieving an average goal blood pressure of <130/80 mm Hg may be associated with improved perinatal outcomes.
PMID: 39288828
ISSN: 1097-6868
CID: 5720532
Roy K. Greenberg and His Work on Endovascular Aortic Aneurysm Repair
Tan, Sally; Hines, George L
PMID: 39898645
ISSN: 1538-4683
CID: 5783702
Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation Therapy
Lischalk, Jonathan W; Santos, Vianca F; Vizcaino, Brianna; Sanchez, Astrid; Mendez, Christopher; Maloney-Lutz, Kathleen; Serouya, Sam; Blacksburg, Seth R; Carpenter, Todd; Tam, Moses; Niglio, Scott; Huang, William; Taneja, Samir; Zelefsky, Michael J; Haas, Jonathan A
PURPOSE/UNASSIGNED:Screening colonoscopies (CS) performed before prostate stereotactic body radiation therapy (SBRT) allow for identifying synchronous malignancies and comorbid gastrointestinal (GI) conditions. Performing these procedures prior to radiation precludes the necessity of post-SBRT pelvic instrumentation, which may lead to severe toxicity and fistulization. We review compliance of CSs, incidence of GI pathology, and the impact of pretreatment CS findings on subsequent physician-reported toxicity and patient-reported quality of life (QoL). METHODS AND MATERIALS/UNASSIGNED:We reviewed an institutional database of patients treated for prostate cancer with SBRT including toxicity and QoL outcomes. A detailed review of pretreatment CS findings was reviewed including identification of diverticulosis, location of polyp resection, and presence of hemorrhoids. Pretreatment CS findings were then correlated with outcomes following SBRT. RESULTS/UNASSIGNED:Identification of comorbid GI conditions was a common event, with the presence of diverticulosis in 49.5% (n = 100), hemorrhoids in 67% (n = 136), and polyps in 48% (n = 98). More than half of patients with polyps removed had at least 1 removed from the rectosigmoid. Pretreatment CS did not introduce a delay in SBRT start date. Grade 1 toxicity was significantly lower in patients who underwent CS closer to the initiation of SBRT. There was no increased risk of physician-graded toxicity in the presence of diverticulosis, hemorrhoids, or polyps. Patient-reported GI QoL pattern in our screening cohort mimicked that seen in the previously published nonscreened population. There was no overt QoL detriment observed in patients who had GI pathology identified before SBRT. CONCLUSIONS/UNASSIGNED:GI pathology identified in our elderly patient population was commonly identified on pretreatment CS. Screening CS may optimize bowel health for patients heading into radiation therapy. Toxicity and QoL for patients with GI pathologies identified on pretreatment CS do not preclude the delivery of prostate SBRT. We advocate for pretreatment CS in patients eligible prior to SBRT.
PMCID:12019482
PMID: 40276629
ISSN: 2452-1094
CID: 5830692
Renal bleeding: imaging and interventions in patients with tumors
Singer, Emad D; Karbasian, Niloofar; Katz, Douglas S; Wong, Vincenzo K; Abdelsalam, Mohamed E; Stanietzky, Nir; Nguyen, Trinh T; Shenoy-Bhangle, Anuradha S; Badawy, Mohamed; Revzin, Margarita V; Shehata, Mostafa A; Eltaher, Mohamed; Elsayes, Khaled M; Korivi, Brinda Rao
In patients with cancer, spontaneous renal bleeding can stem from a range of underlying factors, necessitating precise diagnostic tools for effective patient management. Benign and malignant renal tumors are among the primary culprits, with angiomyolipomas and renal cell carcinomas being the most common among them. Vascular anomalies, infections, ureteral obstructions, and coagulation disorders can also contribute to renal-related bleeding. Cross-sectional imaging techniques, particularly ultrasound and computed tomography (CT), play pivotal roles in the initial detection of renal bleeding. Magnetic resonance imaging and CT are preferred for follow-up evaluations and aid in detecting underlying enhancing masses. IV contrast-enhanced ultrasound can provide additional information for active bleeding detection and differentiation. This review article explores specific disorders associated with or resembling spontaneous acute renal bleeding in patients with renal tumors; it focuses on the significance of advanced imaging techniques in accurately identifying and characterizing renal bleeding in these individuals. It also provides insights into the clinical presentations, imaging findings, and treatment options for various causes of renal bleeding, aiming to enhance the understanding, diagnosis, and management of the issue.
PMID: 38874163
ISSN: 1305-3612
CID: 5669462